Bartlett & Co Wealth Management’s TG Therapeutics TGTX Stock Holding History

Bartlett & Co Wealth Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-25,000	Closed	-$585K	–	1153
2024 Q3	$585K	Hold	25,000	–	–	0.01%	311
2024 Q2	$445K	Hold	25,000	–	–	0.01%	337
2024 Q1	$380K	Hold	25,000	–	–	0.01%	364
2023 Q4	$441K	Hold	25,000	–	–	0.01%	365
2023 Q3	$209K	Hold	25,000	–	–	﹤0.01%	438
2023 Q2	$621K	Hold	25,000	–	–	0.01%	315
2023 Q1	$376K	Hold	25,000	–	–	0.01%	311
2022 Q4	$296K	Hold	25,000	–	–	0.01%	344
2022 Q3	$148K	Buy	+25,000	New	+$164K	﹤0.01%	410

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bartlett & Co Wealth Management's TGTX Position: Q4 2024 in Review

Bartlett & Co Wealth Management sold out of TG Therapeutics (TGTX) in Q4 2024, closing a stake of 25,000 shares — an estimated $585K sold.

Bartlett & Co Wealth Management first reported a position in TGTX in Q3 2022 and held it in 9 quarters. The position peaked at $621K in Q2 2023. 331 funds tracked by Wall St. Rank hold TGTX as of Q4 2024.

Bartlett & Co Wealth Management reported no remaining TG Therapeutics position as of Q4 2024 after selling out during the quarter.
Bartlett & Co Wealth Management sold 25,000 TG Therapeutics shares in Q4 2024, an estimated $585K.
Bartlett & Co Wealth Management first reported a position in TG Therapeutics in Q3 2022 and held it in 9 quarters.
Bartlett & Co Wealth Management's TG Therapeutics position peaked at $621K in Q2 2023.
331 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2024.

Based on Bartlett & Co Wealth Management's 13F filing for Q4 2024, filed 17 Jan 2025.